I don't think they would accept a $15 offer. ANCHOR has 10X the market potential than MARINE does and MARINE's main competitor sells 1B per year and it is an inferior drug. Manipulation of this stock has presented a very good opportunity to load up on cheepies IMO. I think if ANCHOR gets approved and sales start coming in strong, BP will be fighting for it for $25 or more.
ELN didn't really sell for $16/shr - they have $3.66/shr in cash, so the real price was $12.34/shr, a tad higher than Royalty Pharma's $13/shr cash offer, which was of course also only a bid of $9.64/shr.